Fulltext

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

Munzone, E. ; Giobbie-Hurder, A. ; Gusterson, B. A. ; Mallon, E. ; Viale, G. ; Thürlimann, B. ; Ejlertsen, B. ; MacGrogan, G. ; Bibeau, F. ; Lelkaitis, G. ; Price, K. N. ; Gelber, R. D. ; Coates, A. S. ; Goldhirsch, A. ; Colleoni, M.

In: Annals of Oncology, 2015, vol. 26, no. 12, p. 2442-2449

Ajouter à la liste personnelle
    Titre
    • Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
    Auteur
    • Munzone, E.. Division of Medical Senology, European Institute of Oncology, Milan, Italy
    • Giobbie-Hurder, A.. Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA
    • Gusterson, B. A.. Institute of Cancer Sciences, Glasgow University, Glasgow
    • Mallon, E.. Southern General Hospital, Glasgow, UK
    • Viale, G.. Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy
    • Thürlimann, B.. Breast Center, Kantonsspital, St Gallen
    • Ejlertsen, B.. Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark
    • MacGrogan, G.. Department of Pathology, Institut Bergonié, Bordeaux
    • Bibeau, F.. Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France
    • Lelkaitis, G.. Department of Pathology, Rigshospitalet, Copenhagen, Denmark
    • Price, K. N.. International Breast Cancer Study Group (IBCSG) Statistical Center
    • Gelber, R. D.. Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA
    • Coates, A. S.. International Breast Cancer Study Group, Bern, Switzerland
    • Goldhirsch, A.. Program of Breast Health, European Institute of Oncology, Milan, Italy
    • Colleoni, M.. Division of Medical Senology, European Institute of Oncology, Milan, Italy
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2015, vol. 26, no. 12, p. 2442-2449. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291452
    Summary
    In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes